MDS Provides Update on Review of Montreal Bioanalytical Operations
31 Marzo 2006 - 4:00PM
PR Newswire (US)
TORONTO, March 31 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS;
NYSE: MDZ) today provided an update of its retrospective review of
bioanalytical studies conducted in its Montreal facility from 2000
through 2004, following a recent audit by the FDA. The audit
identified a number of issues pertaining to the effectiveness and
management of the five-year review. MDS is working diligently to
meet all FDA expectations and is committed to resolving all
outstanding issues in a timely manner. In order to enhance this
effort, MDS is bringing in experienced project management from
outside the MDS Pharma Services division and will voluntarily wind
down all commercial bioanalytical liquid chromatography/mass
spectrometry operations in Montreal. This will allow for complete
focus to accelerate the activities related to this review.
Commercial activities will continue in MDS Pharma Service's other
bioanalytical sites in Lincoln, Nebraska; Blainville, Quebec;
Zurich, Switzerland; and Sittingbourne, United Kingdom. Stephen P.
DeFalco, President and Chief Executive Officer, MDS Inc. commented,
"I am disappointed that we have not made progress at the rate
necessary on this review. We are enhancing the leadership and
project management of this effort in order to complete this review
to the FDA's satisfaction. Finalizing this effort in a high quality
way is the top priority for the Company." About MDS Inc. MDS Inc.
(TSX: MDS; NYSE: MDZ) has more than 8,800 highly skilled people in
27 countries. We provide a diverse range of superior products and
services to increase our customers' speed, precision and
productivity in the drug development and disease diagnosis
processes. We are a global, values-driven life sciences company,
recognized for our reliability and collaborative relationships as
we help create better outcomes in the treatment of disease. Find
out more at http://www.mdsinc.com/ or by calling 1-800-MDS-7222, 24
hours a day. DATASOURCE: MDS Inc. CONTACT: Sharon Mathers,
Vice-President, Investor Relations, (416) 675-6777 ext. 2695,
Copyright